Clinical Trial Update: A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II open-label dose-escalation trial of CPI-613 (devimistat) with gemcitabine in cancer patients; the study is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• CPI-613 (devimistat)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Cornerstone Pharmaceuticals | Conditions: Cancer, Pancreatic Cancer | Phase 1, Phase 2 | Status: TERMINATED